#1 Clinical Trials Search in Europe

Ponatinib

Ponatinib is a targeted therapy drug being studied in clinical trials for the treatment of various types of cancer, including chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), and solid tumors. This article summarizes key information from several clinical trials investigating the safety and effectiveness of ponatinib in different patient populations and cancer types.

Table of Contents

What is Ponatinib?

Ponatinib is a medication used to treat certain types of blood cancers. It is also known by its brand name Iclusig and is sometimes referred to as AP24534 or INCB84344 in scientific literature[1][2]. Ponatinib is classified as a tyrosine kinase inhibitor (TKI), which is a type of drug that blocks specific proteins involved in cancer growth[3].

How Ponatinib Works

Ponatinib works by targeting and blocking an abnormal protein called BCR-ABL, which is responsible for causing certain types of leukemia. This protein is created when two genes, BCR and ABL, accidentally fuse together. By inhibiting this protein, Ponatinib can help stop the growth and spread of cancer cells[3].

Additionally, Ponatinib is designed to be effective against a specific mutation called T315I, which can make leukemia cells resistant to other TKI treatments[2]. This makes Ponatinib particularly valuable for patients who have not responded well to other treatments.

Conditions Treated with Ponatinib

Ponatinib is primarily used to treat the following conditions:

  • Chronic Myeloid Leukemia (CML): A type of blood cancer that affects the bone marrow and blood cells. Ponatinib can be used to treat CML in various phases, including:
    • Chronic Phase (CP-CML)
    • Accelerated Phase (AP-CML)
    • Blast Phase (BP-CML)
  • Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL): A type of leukemia that affects lymphoid cells and is characterized by the presence of the Philadelphia chromosome[4].

Ponatinib is often used when patients have become resistant or intolerant to other TKI treatments, or when they have developed the T315I mutation[5].

How Ponatinib is Administered

Ponatinib is taken orally as a tablet, usually once daily. The typical starting dose is 45 mg per day, but this can vary depending on the specific condition being treated and the patient’s response to the medication[5]. Some key points about taking Ponatinib include:

  • It can be taken with or without food
  • It should be taken at approximately the same time each day
  • Patients should not eat within 2 hours before or after taking the drug
  • If a dose is missed, the next dose should not be doubled to make up for it[3]

The duration of treatment can vary, but some studies have investigated treatment periods of up to 5 years[3].

Efficacy of Ponatinib

Clinical trials have shown that Ponatinib can be effective in treating CML and Ph+ ALL, particularly in patients who have not responded well to other treatments. Some measures of efficacy include:

  • Major Cytogenetic Response (MCyR): This refers to a significant reduction in the number of cells with the Philadelphia chromosome[2].
  • Major Molecular Response (MMR): This indicates a substantial decrease in the level of BCR-ABL transcripts, which are markers of leukemia activity[5].
  • Complete Hematologic Response (CHR): This means that blood cell counts have returned to normal levels[5].

The effectiveness of Ponatinib can vary depending on the specific condition, phase of the disease, and individual patient factors.

Potential Side Effects

Like all medications, Ponatinib can cause side effects. Some of the most significant potential side effects include:

  • Blood Clots: Ponatinib may increase the risk of blood clots forming in arteries or veins. This can potentially lead to serious complications such as heart attack or stroke[3].
  • Cardiovascular Events: There is a risk of heart-related problems, including heart attacks and narrowing of blood vessels[5].
  • Liver Problems: Ponatinib can affect liver function, so regular monitoring may be required.
  • Pancreatic Issues: Some patients may experience inflammation of the pancreas.
  • Skin Reactions: Rashes or other skin problems can occur.

It’s important to note that not all patients will experience these side effects, and many side effects can be managed with proper medical care. Patients should always report any unusual symptoms to their healthcare provider.

Ongoing Research

Researchers continue to study Ponatinib to better understand its effectiveness and safety profile. Some areas of ongoing research include:

  • Investigating different dosing strategies to maximize effectiveness while minimizing side effects[5].
  • Exploring the use of Ponatinib in other types of cancer, such as certain lung cancers and thyroid cancers[6][7].
  • Studying the long-term effects and outcomes of Ponatinib treatment[2].
  • Investigating the use of Ponatinib in pediatric patients with certain types of leukemia[1].

These ongoing studies aim to improve our understanding of Ponatinib and potentially expand its use to help more patients with various types of cancer.

Cancer Type Trial Phase Key Findings
CML and Ph+ ALL Phase 2 Effective in patients resistant to other TKIs or with T315I mutation; dose-dependent efficacy and safety profile
Lung Cancer Phase 2 Studied in patients with specific biomarkers; results pending
Glioblastoma Phase 2 Investigated in bevacizumab-refractory patients; assessing tumor response and progression-free survival
Pediatric Leukemias and Solid Tumors Phase 1/2 Evaluating safety, tolerability, and efficacy in children aged 1 to <18 years
Medullary Thyroid Cancer Phase 2 Studying efficacy in advanced or metastatic disease; assessing objective response rate
Endometrial Cancer Phase 2 Investigating effectiveness in FGFR mutation-positive recurrent or persistent cases

FAQ

  • What is ponatinib and how does it work? Ponatinib is a targeted therapy drug that blocks abnormal cancer proteins, specifically designed to inhibit the BCR-ABL protein responsible for causing certain types of leukemia. It works by stopping the growth of cancer cells by blocking enzymes needed for cell growth.
  • What types of cancer is ponatinib being studied for? Ponatinib is being studied in clinical trials for various cancers, including chronic myeloid leukemia (CML), Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), lung cancer, glioblastoma, medullary thyroid cancer, and endometrial cancer.
  • What are the common side effects of ponatinib? Common side effects of ponatinib include blood clots in arteries or veins, which can lead to serious complications. Other side effects may include fatigue, skin rashes, and gastrointestinal issues. The specific side effects and their frequency vary depending on the dose and individual patient factors.
  • How is ponatinib administered? Ponatinib is typically administered as an oral tablet taken once daily. The dosage may vary depending on the specific clinical trial and patient characteristics, ranging from 15 mg to 45 mg per day.
  • What is the goal of ponatinib clinical trials? The main goals of ponatinib clinical trials are to determine its effectiveness in treating various cancers, establish optimal dosing regimens, evaluate safety profiles, and assess patient outcomes such as response rates, progression-free survival, and overall survival.

Ongoing Clinical Trials on Ponatinib

  • Study of olverembatinib with chemotherapy versus standard therapy in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Czechia France Greece Hungary Italy +2

  • Study Comparing Ponatinib and Imatinib with Chemotherapy for Patients 55+ with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

    Recruiting

    2 1 1 1
    Investigated drugs:
    Finland France Sweden

  • Study of Inotuzumab Ozogamicin and drug combination in adult patients with B-cell Acute Lymphoblastic Leukemia who have minimal residual disease before stem cell transplantation

    Recruiting

    2 1 1 1
    Investigated drugs:
    Italy

  • Study of Drug Combination for Advanced Cancer Patients with Known Molecular Profile – FINPROVE Study

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Finland

  • Study on Ponatinib and Imatinib for Adults with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia

    Recruiting

    2 1 1 1
    Investigated drugs:
    Germany

  • Study on Ponatinib for Treating Recurrent or Refractory Leukemias and Solid Tumors in Children

    Recruiting

    1 1 1 1
    Investigated drugs:
    Belgium France Italy The Netherlands Spain Sweden

  • Study of Ponatinib and Chemotherapy for Adults with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

    Recruiting

    2 1 1 1
    Investigated drugs:
    Italy

  • Study on Blinatumomab, Ponatinib, and Isatuximab for Adults Aged 18-65 with Newly Diagnosed Acute Lymphoblastic Leukemia or T-Cell Lymphoblastic Lymphoma

    Recruiting

    4 1 1 1
    Investigated drugs:
    Belgium France

  • Safety and effectiveness of ponatinib and asciminib in chronic myeloid leukemia patients resistant to these drugs

    Not yet recruiting

    2 1 1 1
    Investigated drugs:
    Spain

  • Study on Ponatinib for Achieving Treatment-Free Remission in Patients with Chronic Myeloid Leukemia

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

Glossary

  • Chronic Myeloid Leukemia (CML): A type of blood cancer that begins in the bone marrow and affects the production of white blood cells.
  • Philadelphia Chromosome-Positive (Ph+): A genetic abnormality associated with certain types of leukemia, particularly CML and some cases of ALL.
  • Tyrosine Kinase Inhibitor (TKI): A class of drugs that block specific enzymes called tyrosine kinases, which are involved in cancer cell growth and survival.
  • BCR-ABL: An abnormal protein produced by the Philadelphia chromosome, which is responsible for the uncontrolled growth of leukemia cells in CML and some cases of ALL.
  • T315I Mutation: A specific genetic mutation that can make leukemia cells resistant to certain tyrosine kinase inhibitors, but which may be sensitive to ponatinib.
  • Cytogenetic Response: A measure of treatment effectiveness based on the reduction of cancer cells with the Philadelphia chromosome in the bone marrow.
  • Molecular Response: A measure of treatment effectiveness based on the reduction of BCR-ABL transcript levels in the blood or bone marrow.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives without the cancer progressing or getting worse.
  • Overall Survival (OS): The length of time from the start of treatment that patients are still alive.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.

References

  1. https://clinicaltrials.gov/study/NCT03934372
  2. https://clinicaltrials.gov/study/NCT01207440
  3. https://clinicaltrials.gov/study/NCT01570868
  4. https://clinicaltrials.gov/study/NCT01592136
  5. https://clinicaltrials.eu/trial/study-of-ponatinib-for-patients-with-resistant-chronic-myeloid-leukemia/
  6. https://clinicaltrials.gov/study/NCT01935336
  7. https://clinicaltrials.gov/study/NCT03838692